JP2024542085A5 - - Google Patents

Info

Publication number
JP2024542085A5
JP2024542085A5 JP2024526560A JP2024526560A JP2024542085A5 JP 2024542085 A5 JP2024542085 A5 JP 2024542085A5 JP 2024526560 A JP2024526560 A JP 2024526560A JP 2024526560 A JP2024526560 A JP 2024526560A JP 2024542085 A5 JP2024542085 A5 JP 2024542085A5
Authority
JP
Japan
Application number
JP2024526560A
Other languages
Japanese (ja)
Other versions
JP2024542085A (ja
JPWO2023079507A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2022/060639 external-priority patent/WO2023079507A1/en
Publication of JP2024542085A publication Critical patent/JP2024542085A/ja
Publication of JP2024542085A5 publication Critical patent/JP2024542085A5/ja
Publication of JPWO2023079507A5 publication Critical patent/JPWO2023079507A5/ja
Pending legal-status Critical Current

Links

JP2024526560A 2021-11-05 2022-11-04 呼吸器合胞体ウイルスrnaワクチン Pending JP2024542085A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163276233P 2021-11-05 2021-11-05
US63/276,233 2021-11-05
EP22315065.7 2022-03-16
EP22315065 2022-03-16
PCT/IB2022/060639 WO2023079507A1 (en) 2021-11-05 2022-11-04 Respiratory syncytial virus rna vaccine

Publications (3)

Publication Number Publication Date
JP2024542085A JP2024542085A (ja) 2024-11-13
JP2024542085A5 true JP2024542085A5 (https=) 2025-11-11
JPWO2023079507A5 JPWO2023079507A5 (https=) 2025-11-11

Family

ID=84357817

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024526560A Pending JP2024542085A (ja) 2021-11-05 2022-11-04 呼吸器合胞体ウイルスrnaワクチン

Country Status (12)

Country Link
US (1) US20230302112A1 (https=)
EP (1) EP4426343A1 (https=)
JP (1) JP2024542085A (https=)
KR (1) KR20240107146A (https=)
AR (1) AR127585A1 (https=)
AU (1) AU2022382104A1 (https=)
CA (1) CA3236924A1 (https=)
CO (1) CO2024005145A2 (https=)
IL (1) IL312334A (https=)
MX (1) MX2024005462A (https=)
TW (1) TW202346593A (https=)
WO (1) WO2023079507A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022099003A1 (en) 2020-11-06 2022-05-12 Sanofi Lipid nanoparticles for delivering mrna vaccines
WO2023018831A2 (en) 2021-08-11 2023-02-16 RNAimmune, Inc. Composition and methods of mrna vaccines against novel coronavirus infection
US12280104B2 (en) 2022-11-01 2025-04-22 RNAimmune, Inc. Composition and methods for MRNA vaccines against novel omicron coronavirus infections
CN121712487A (zh) * 2023-06-28 2026-03-20 赛诺菲巴斯德有限公司 脂质纳米颗粒配制品中的固醇类似物
WO2025003754A1 (en) * 2023-06-28 2025-01-02 Sanofi Use of glycerides for lnp formulations
WO2025024336A1 (en) * 2023-07-21 2025-01-30 RNAimmune, Inc. Compositions and methods of ribonucleic acid respiratory syncytial virus (rsv) vaccines
CN119490569A (zh) * 2023-08-16 2025-02-21 深圳瑞吉生物科技有限公司 呼吸道合胞病毒抗原性多肽、核酸、疫苗及其应用
CN119504955A (zh) * 2023-08-25 2025-02-25 深圳瑞吉生物科技有限公司 呼吸道合胞病毒抗原性多肽、核酸及疫苗
CN119979573A (zh) * 2023-11-03 2025-05-13 纳美信(上海)生物科技有限公司 一种呼吸道合胞病毒mRNA疫苗
CN120022355A (zh) * 2023-11-22 2025-05-23 长春百克生物科技股份公司 一种mRNA疫苗及其应用
CN120227354A (zh) * 2023-12-29 2025-07-01 康希诺(上海)生物研发有限公司 一种用于递送核酸的脂质纳米颗粒及其制备方法和用途
CN118440937B (zh) * 2024-04-09 2025-02-25 嘉译生物医药(杭州)有限公司 新型的人合胞病毒RSV B mRNA疫苗
CN119144620B (zh) * 2024-08-29 2025-08-19 北京康乐卫士生物技术股份有限公司 呼吸道合胞病毒mRNA疫苗及其制备方法和应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US5132418A (en) 1980-02-29 1992-07-21 University Patents, Inc. Process for preparing polynucleotides
US4668777A (en) 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
US4415732A (en) 1981-03-27 1983-11-15 University Patents, Inc. Phosphoramidite compounds and processes
US4973679A (en) 1981-03-27 1990-11-27 University Patents, Inc. Process for oligonucleo tide synthesis using phosphormidite intermediates
US4401796A (en) 1981-04-30 1983-08-30 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US4373071A (en) 1981-04-30 1983-02-08 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US5153319A (en) 1986-03-31 1992-10-06 University Patents, Inc. Process for preparing polynucleotides
US5262530A (en) 1988-12-21 1993-11-16 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5047524A (en) 1988-12-21 1991-09-10 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
ATE509102T1 (de) 1994-07-15 2011-05-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5700642A (en) 1995-05-22 1997-12-23 Sri International Oligonucleotide sizing using immobilized cleavable primers
US5744335A (en) 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
AU7690898A (en) 1997-05-20 1998-12-11 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
ATE356630T1 (de) 1998-04-03 2007-04-15 Univ Iowa Res Found Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine
EP1751289B1 (en) 2004-05-18 2009-01-14 Alphavax, Inc. Tc-83-derived alphavirus vectors, particles and methods
US20110300205A1 (en) 2009-07-06 2011-12-08 Novartis Ag Self replicating rna molecules and uses thereof
HUE042177T2 (hu) 2009-12-01 2019-06-28 Translate Bio Inc Szteroidszármazék mRNS szállítására humán genetikai betegségekben
WO2012075040A2 (en) 2010-11-30 2012-06-07 Shire Human Genetic Therapies, Inc. mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
PL3586861T3 (pl) 2011-06-08 2022-05-23 Translate Bio, Inc. Kompozycje nanocząstek lipidowych i sposoby dostarczania mrna
KR102451116B1 (ko) 2011-10-27 2022-10-06 메사추세츠 인스티튜트 오브 테크놀로지 약물 캡슐화 마이크로스피어를 형성할 수 있는, n-말단 상에 관능화된 아미노산 유도체
US10245229B2 (en) 2012-06-08 2019-04-02 Translate Bio, Inc. Pulmonary delivery of mRNA to non-lung target cells
US9738689B2 (en) * 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
CN105051213A (zh) 2013-03-14 2015-11-11 夏尔人类遗传性治疗公司 信使rna加帽效率的定量评估
US10130649B2 (en) 2013-03-15 2018-11-20 Translate Bio, Inc. Synergistic enhancement of the delivery of nucleic acids via blended formulations
SG11201510747RA (en) 2013-08-21 2016-03-30 Curevac Ag Method for increasing expression of rna-encoded proteins
ES2806575T3 (es) 2013-11-01 2021-02-18 Curevac Ag ARN modificado con propiedades inmunoestimuladoras disminuidas
KR102399799B1 (ko) 2013-12-30 2022-05-18 큐어백 아게 인공 핵산 분자
CA2927254C (en) 2013-12-30 2023-10-24 Curevac Ag Artificial nucleic acid molecules
BR112016030852A2 (pt) 2014-07-02 2018-01-16 Shire Human Genetic Therapies encapsulação de rna mensageiro
DE202015010000U1 (de) 2014-12-12 2023-07-03 CureVac SE Artifizielle Nukleinsäuremoleküle für eine verbesserte Proteinexpression
ES2897823T3 (es) 2015-04-30 2022-03-02 Curevac Ag Poli(N)polimerasa inmovilizada
ES2949540T3 (es) 2015-06-19 2023-09-29 Massachusetts Inst Technology 2,5-piperazinadionas sustituidas con alquenilo y su uso en composiciones para suministrar un agente a un sujeto o una célula
TW201729835A (zh) * 2015-10-22 2017-09-01 現代公司 呼吸道病毒疫苗
WO2017162265A1 (en) 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Trans-replicating rna
MX2019005470A (es) 2016-11-10 2019-11-21 Translate Bio Inc Formulación de nanopartículas lipídicas basadas en ice mejorada para el suministro de arnm.
WO2018089801A1 (en) 2016-11-10 2018-05-17 Translate Bio, Inc. Improved process of preparing mrna-loaded lipid nanoparticles
EP3595713A4 (en) * 2017-03-15 2021-01-13 ModernaTX, Inc. RESPIRATORY SYNCYTIAL VIRUS Vaccine
WO2019148101A1 (en) * 2018-01-29 2019-08-01 Modernatx, Inc. Rsv rna vaccines
BR112020019938A2 (pt) 2018-04-03 2021-01-26 Sanofi polipeptídeos antigênicos de vírus sincicial respiratório
KR20210105889A (ko) * 2018-11-09 2021-08-27 아뷰터스 바이오파마 코포레이션 지질 나노입자 제제
EP4003311A1 (en) 2019-07-23 2022-06-01 Translate Bio, Inc. Stable compositions of mrna-loaded lipid nanoparticles and processes of making

Similar Documents

Publication Publication Date Title
JP2024542085A5 (https=)
JP2024528418A5 (https=)
BR102022025291A2 (https=)
BR102022026909A2 (https=)
BR102022023461A2 (https=)
CN307045406S (https=)
BY13174U (https=)
CN307047683S (https=)
CN307047556S (https=)
CN307046883S (https=)
CN307046322S (https=)
CN307046159S (https=)
CN307049505S (https=)
CN307044980S (https=)
CN307044959S (https=)
CN307044358S (https=)
BY23998C1 (https=)
BY23963C1 (https=)
BY13163U (https=)
BY13175U (https=)
BY13164U (https=)
BY13172U (https=)
BY13170U (https=)
BY13169U (https=)
BY13168U (https=)